Pre-order Enquiry
Request Free Sample
Global Insulin API Market Research Report 2021
SKU ID : QYR-17219625 | Publishing Date : 19-Jan-2021 | No. of pages : 117
Request Sample
Request Customization
Check Discounts
Insulin is used to treat type 1 diabetes (condition in which the body does not produce insulin and therefore cannot control the amount of sugar in the blood). It is also used to treat people with type 2 diabetes (condition in which the body does not use insulin normally and, therefore, cannot control the amount of sugar in blood) who need insulin to control their diabetes. Nowadays, Insulin as an important drug is widely used to treat diabetes.
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API.
Insulin API is widely used in Fast-acting, Intermediate-acting and Long-acting Product. The most proportion of Insulin API is used in Long-acting, and the proportion in 2019 is about 41%.
The global Insulin API market was valued at US$ 1664.2 million in 2019 and is expected to reach US$ 2013.8 million by the end of 2026, growing at a CAGR of 2.9% during 2021-2026.
This report focuses on Insulin API volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Insulin API market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Insulin API Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Regular Human Insulin
Insulin Analogue
Segment by Application
Fast-Acting
Premix
Long-Acting
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
Ganlee
United Laboratory
Biocon
Amphastar
Wockhardt
Julphar Diabetes
Torrent Pharma
In China and Chinese insulin market, animal insulin, called first generation insulin, has been almost replaced by new type generation insulin. Basing on the trend of China and Chinese insulin industry, this report researches the market of human insulin and insulin analogue in China.
In this report, the statistics of insulin industry is based on Insulin API, the physical features of insulin API is Freeze-dried powder. The weight unite of insulin API weight is Kg in this report.
The main production are concentrated in Novo Nordisk, Eli Lilly, Sanofi. Gan Lee Tonghua Dongbao in recent years to expand production capacity, and they are the main providers of insulin API.
Insulin API is widely used in Fast-acting, Intermediate-acting and Long-acting Product. The most proportion of Insulin API is used in Long-acting, and the proportion in 2019 is about 41%.
The global Insulin API market was valued at US$ 1664.2 million in 2019 and is expected to reach US$ 2013.8 million by the end of 2026, growing at a CAGR of 2.9% during 2021-2026.
This report focuses on Insulin API volume and value at the global level, regional level and company level. From a global perspective, this report represents overall Insulin API market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, Asia-Pacific, Latin America and Middle East & Africa.
Global Insulin API Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2016 to 2027. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Regular Human Insulin
Insulin Analogue
Segment by Application
Fast-Acting
Premix
Long-Acting
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Novo Nordisk
Sanofi-Aventis
Eli Lilly
Tonghua Dongbao
Ganlee
United Laboratory
Biocon
Amphastar
Wockhardt
Julphar Diabetes
Torrent Pharma
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
